CHINARES PHARMA Successfully Issues Inaugural Medium-Term Note Series

Stock News
07/22

CHINARES PHARMA has announced the successful issuance of its inaugural medium-term note series.

The company's wholly-owned subsidiary has completed the domestic issuance of the first series of 2026 medium-term notes.

The notes carry a total principal value of RMB 1.0 billion with a three-year term and an annual coupon rate set at 1.53%.

Proceeds from the issuance are designated for supplementing working capital, repaying interest-bearing debt, and other purposes compliant with applicable laws and regulations.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10